Get the Stockscreener App
1.25
9.65%
0.11
After Hours:
1.24
-0.01
-0.80%
Ocugen Inc stock is traded at $1.25, with a volume of 4.08M.
It is up +9.65% in the last 24 hours and up +0.00% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.14
Open:
$1.15
24h Volume:
4.08M
Relative Volume:
0.76
Market Cap:
$359.82M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-3.3784
EPS:
-0.37
Net Cash Flow:
$-72.53M
1W Performance:
-3.85%
1M Performance:
+0.00%
6M Performance:
+26.52%
1Y Performance:
+201.35%
1-Day Range:
$1.13
$1.25
1-Week Range:
$1.12
$1.30
52-Week Range:
$0.345
$2.105
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop - Ocugen
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to - GlobeNewswire
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop - StockTitan
Ocugen’s CSO to Highlight Gene Therapy Advances at Upcoming Conference - MSN
Ocugen’s CSO to Highlight Gene Therapy Advances at Upcoming Conference - MyChesCo
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen, Inc. to Engage Investors at H.C. Wainwright Conference - MSN
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit - GlobeNewswire
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit - StockTitan
Ocugen, Inc. to Engage Investors at H.C. Wainwright Conference - MyChesCo
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - Ocugen
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen Advances Gene Therapy Trial for Stargardt Disease - MSN
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Short Interest in Ocugen, Inc. (NASDAQ:OCGN) Decreases By 19.9% - MarketBeat
TSX Information Tech Capped Index (TTTK) QuotePress Release - The Globe and Mail
TSX Materials Capped Index (TTMT) QuotePress Release - The Globe and Mail
Ocugen Advances Gene Therapy Trial for Stargardt Disease - MyChesCo
Ocugen Announces Completion of Dosing in Subjects with - GlobeNewswire
Ocugen rises on completing patient dosing in early-stage gene therapy trial - XM
Ocugen completes dosing in Stargardt disease trial - Investing.com
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy - Ocugen
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy - GlobeNewswire
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy - StockTitan
Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up - MSN
Ocugen Expands Gene Therapy Trial to Canada - MSN
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up - Yahoo Finance
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen advances gene therapy trial for retinitis pigmentosa - Investing.com
Ocugen Gets Health Canada Approval for Phase 3 Trial of Gene Therapy for Retinitis Pigmentosa - MarketWatch
Ocugen advances gene therapy trial for retinitis pigmentosa - Investing.com India
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication - Ocugen
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication - Yahoo Finance UK
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication - Yahoo Finance
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication - GlobeNewswire
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication - StockTitan
OCGN (Ocugen) Enterprise Value : $348.11 Mil (As of Aug. 17, 2024) - GuruFocus.com
Reviewing Sutro Biopharma (NASDAQ:STRO) and Ocugen (NASDAQ:OCGN) - Defense World
Chardan Capital Weighs in on Ocugen, Inc.'s FY2024 Earnings (NASDAQ:OCGN) - MarketBeat
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen - Longview News-Journal
OCGN Investors Have Opportunity to Lead Ocugen, Inc. Securities Fraud Lawsuit - Longview News-Journal
Chardan Capital Research Analysts Raise Earnings Estimates for Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Financial Contrast: Ocugen (NASDAQ:OCGN) & ZIVO Bioscience (NASDAQ:ZIVO) - Defense World
Ocugen Inc. stock rises Tuesday, still underperforms market - MarketWatch
Ocugen, Inc. Forecasted to Post Q4 2024 Earnings of ($0.06) Per Share (NASDAQ:OCGN) - MarketBeat
Tidal Investments LLC Purchases Shares of 66,009 Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.30%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):